このエントリーをはてなブックマークに追加
ID 31932
JaLCDOI
FullText URL
Author
Takahishi, Isao
Yorimitsu, Seiichi
Hara, Masamichi
Inagaki, Toshihiro
Nakada, Hiroyuki
Sekito, Noriko
Hayashi, Naoki
Nonaka, kenichi
Ohmoto, Eijiro
Uchida, Kouzaburo
Takizawa, Michihiro
Kimura, Ikuro
Sanada, Hiroshi
Adachi, Tomiro
Tsubota, Teruhiko
Kitajima, Koichi
Abstract

Thirteen previously untreated patients aged 70 and above with acute nonlymphocytic leukemia were treated with aclarubicin (ACR) alone. Among 10 cases (3, acute myelocytic leukemia; 4, acute myelomonocytic leukemia; 2, acute monocytic leukemia; and one, acute erythroleukemia) in which an evaluation was possible, 5 cases (3, acute myelomonocytic leukemia; and 2, acute monocytic leukemia) obtained complete remission (CR). The CR rate was 83% in 6 patients with acute myelomonocytic leukemia or acute monocytic leukemia. The median CR duration and survival was 7.5 and 10 + months, respectively. Although side effects of the drug on digestive system such as nausea, vomiting and anorexia were observed in all patients, they were controllable by conventional treatments. The results suggest that ACR is effective for the clinical management of elderly patients with acute nonlymphocytic leukemia, especially those with acute myelomonocytic leukemia or acute monocytic leukemia.

Keywords
acute leukemia in elderly patients
chemotherapy of acute leukemia
aclarubicin
Amo Type
Article
Published Date
1986-06
Publication Title
Acta Medica Okayama
Volume
volume40
Issue
issue3
Publisher
Okayama University Medical School
Start Page
175
End Page
177
ISSN
0386-300X
NCID
AA00508441
Content Type
Journal Article
language
英語
File Version
publisher
Refereed
True
PubMed ID
Web of Science KeyUT